Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7%, versus 77.9% in Q4 2024 and 77.6% in Q3 2025. Full year 2025 gross margin was 77.1% versus 75.2% in 2024. GAAP Operating Income was $2.0 million for Q4 2025 and $4.9 million for full year 2025. Company provides guidance for reve ...

Core Insights - Sanuwave Health, Inc. has added its UltraMIST product line to Healogics iSupply, making it available to members including Wound Care Centers, home health agencies, and skilled nursing facilities [1][2] - The rollout of the UltraMIST system to Healogics iSupply members is planned for initial locations by the end of 2025 [2] - Collaboration with Healogics, a leader in wound care treatment and research, is seen as a significant opportunity for Sanuwave to provide innovative solutions to its members [3] Company Overview - Sanuwave Health focuses on the research, development, and commercialization of patented, non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures [4] - The company offers a comprehensive wound care portfolio that aids in restoring normal healing processes through its patented energy transfer technologies [5] Industry Context - Healogics has been a leader in advanced wound care for nearly 30 years, partnering with hospitals and health systems to deliver specialized care for chronic wounds [6] - The organization is backed by the largest wound care outcomes database and the Wound Science Initiative, which supports research and sets new standards in healing [7]

Core Insights - The final rule for the 2026 Physician Fee Schedule by CMS aligns with the proposed rule and shows minimal changes from 2025 rates [1][2][3] - Reimbursement for the CPT code 97610 related to UltraMIST products remains largely unchanged, with payment rates for various treatment settings staying within $2-4 of 2025 levels [2][3] Summary by Sections Reimbursement Rates - The reimbursement for the 97610 code for UltraMIST products is expected to remain materially unchanged for 2026, with rates for physician offices, home visits, long-term care, and hospitals staying within $2-4 of 2025 rates [2] - Changes for 2026 are anticipated to be less than 1%, with many providers likely to see a slight increase in reimbursement [3] Company Response - In response to inquiries regarding UltraMIST reimbursement rates, the company provided an update confirming that the final 2026 rates are consistent with prior expectations [3] - The company plans to discuss these developments further during its third quarter earnings call [3]

Core Insights - Sanuwave Health, Inc. reported preliminary revenues of $11.4 million to $11.6 million for Q3 2025, marking the highest quarterly revenues in the company's history [1][2] - The revenue for Q3 2025 reflects an increase of 22% to 24% compared to Q3 2024 and a sequential increase of 12% to 14% from the previous quarter [1][2] - For the first nine months of 2025, revenue increased by 39% to 40% compared to the same period in 2024 [1] Revenue Guidance - The company has revised its 2025 annual revenue guidance from $48 million to $50 million down to $44 million to $46 million due to challenges faced in Q3 [3] - The Q3 performance was impacted by uncertainties surrounding proposed reimbursement changes in the wound care market, particularly affecting skin substitutes and grafts [3] Market Conditions - CEO Morgan Frank noted that the wound care market experienced a "wait and see" approach from providers, leading to delayed purchase decisions and reduced patient counts [3] - Despite these challenges, Sanuwave achieved record system sales in Q3, with September being the highest revenue month in the company's history [3] Reimbursement Insights - The UltraMIST reimbursement is not expected to be affected by potential changes in allograft reimbursement, with a slight increase anticipated for the 97610 code in 2026 compared to 2025 [4] - The current disruption in the market is viewed as a near-term challenge but also represents a significant future opportunity for the company [4] Upcoming Events - A conference call to discuss the Q3 results is scheduled for October 6, 2025, at 5:30 PM ET, with full Q3 results expected to be released around November 7, 2025 [5][6]

Q1 FY2024 May 10, 2024 Live Presentation Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1665712&tp_key=5ceebf04ab Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 1155590 Friday, May 10, 2024, 8:30 AM (ET) Replay Expiry: June 3, 2024 2 Forward Looking Statements This presentation may contain "forward- ...

As filed with the Securities and Exchange Commission on December 3, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) (State or other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Nevada 3841 20-1176000 (I.R.S. Employer Identification No.) 11495 Valley View Road ...